Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 2.08 10.05% 0.19
ACRX closed up 10.05 percent on Wednesday, February 24, 2021, on 43 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ACRX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 10.05%
50 DMA Support Bullish 10.05%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 10.05%
Doji - Bullish? Reversal 10.05%
Wide Bands Range Expansion 10.05%
Below Lower BB Weakness 10.05%
Gapped Down Weakness 10.05%
Lower Bollinger Band Touch Weakness 10.05%
Older End-of-Day Signals for ACRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 10% about 19 hours ago
Gap Up Partially Closed about 20 hours ago
Gapped Up (Full) about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AcelRx Pharmaceuticals, Inc. Description

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Pain Treatment Of Cancer Chemical Compounds Organic Compounds Injury Clinical Trial Mild Ethers Stage Specialty Pharmaceutical Acute Pain Piperidines Fentanyl Breakthrough Pain Sufentanil Thiophenes

Is ACRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.94
52 Week Low 0.7014
Average Volume 6,826,409
200-Day Moving Average 1.51
50-Day Moving Average 1.86
20-Day Moving Average 2.30
10-Day Moving Average 2.27
Average True Range 0.25
ADX 32.52
+DI 26.37
-DI 27.40
Chandelier Exit (Long, 3 ATRs ) 2.19
Chandelier Exit (Short, 3 ATRs ) 2.51
Upper Bollinger Band 2.74
Lower Bollinger Band 1.87
Percent B (%b) 0.25
BandWidth 37.83
MACD Line 0.04
MACD Signal Line 0.13
MACD Histogram -0.0846
Fundamentals Value
Market Cap 188.19 Million
Num Shares 90.5 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -2.93
Price-to-Sales 23.25
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.35
Resistance 3 (R3) 2.35 2.25 2.31
Resistance 2 (R2) 2.25 2.18 2.26 2.29
Resistance 1 (R1) 2.17 2.14 2.21 2.17 2.27
Pivot Point 2.07 2.07 2.10 2.08 2.07
Support 1 (S1) 1.99 2.00 2.03 1.99 1.89
Support 2 (S2) 1.89 1.96 1.90 1.87
Support 3 (S3) 1.81 1.89 1.86
Support 4 (S4) 1.81